Page last updated: 2024-12-06
letrazuril
Description
Letrazuril is a synthetic anticoccidial drug used to treat coccidiosis in animals, particularly in poultry and cattle. It acts by inhibiting the growth and development of coccidia parasites, which are protozoa that cause intestinal infections and can lead to significant economic losses in livestock production. Letrazuril is effective against a wide range of coccidia species, including Eimeria spp. in poultry and cattle. Its mechanism of action involves interfering with the parasite's mitochondrial electron transport chain, leading to energy depletion and ultimately parasite death. Letrazuril is typically administered orally in feed or water, and it has a long duration of action, providing protection against coccidiosis for several weeks. The drug has been shown to be safe and effective in numerous studies, and it is widely used in the livestock industry. Letrazuril's effectiveness, safety, and wide spectrum of activity have made it a valuable tool for preventing and controlling coccidiosis in animals. It has contributed to improved animal health, reduced economic losses, and enhanced food production.'
```
letrazuril: effective against Cryptosporidium infections [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 59745 |
| CHEMBL ID | 2104819 |
| SCHEMBL ID | 466345 |
| MeSH ID | M0215577 |
Synonyms (26)
| Synonym |
|---|
| letrazuril [inn] |
| 2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]-2-(4-fluorophenyl)acetonitrile |
| [2,6-dichloro-4-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3h)-yl)phenyl](4-fluorophenyl)acetonitrile |
| CHEMBL2104819 |
| (+-)-(2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-as-triazin-2(3h)-yl)phenyl)(p-fluorophenyl)acetonitrile |
| u8736vcb22 , |
| letrazurilo [inn-spanish] |
| letrazurilum [inn-latin] |
| unii-u8736vcb22 |
| letrazurilo |
| letrazuril |
| 103337-74-2 |
| letrazurilum |
| (+/-)-(2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-as-triazin-2(3h)-yl)phenyl)(p-fluorophenyl)acetonitrile |
| letrazuril [mart.] |
| SCHEMBL466345 |
| CS-7795 |
| c17h9cl2fn4o2 |
| HY-106859 |
| DB12663 |
| DTXSID60869392 |
| 2-(2,6-dichloro-4-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3h)-yl)phenyl)-2-(4-fluorophenyl)acetonitrile |
| W18799 |
| Q27290829 |
| AS-56245 |
| AKOS037645026 |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 3 (50.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 1 (16.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |